Latest Peplin news

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

Letter to our CDI Holders read more

Archived 2004

24-12-2004	Resignation of Jim Aylward	26 Kb
09-12-2004	Rights issue subscriptions	33 Kb
08-11-2004	Underwritten rights issue to raisae $10.2 million	4 Kb
25-10-2004	Phase I clinical trial completes ahead of schedule	35 Kb
12-10-2004	Peplin to present at the BIO Emerging Company Investor Forum	35 Kb
08-10-2004	Change of Company Name	507 Kb
08-10-2004	Peplin assumes control of skin cancer product	52 Kb
08-10-2004	Suspension of trade lifted	15 Kb
08-10-2004	ALLERGAN NEWS RELEASE: Allergan announces agreement to discontinue Peplin collaboration	59 Kb
04-10-2004	Suspension of trading/ASX Market Release	37 Kb
28-09-2004	Address by the Chairman to Peplin's AGM	40 Kb
28-09-2004	Peplin's AGM: All resolutions approved by shareholders	34 Kb
21-09-2004	Peplin granted US patent for its products against all cancers	38 Kb
27-08-2004	Initiation of human trials	33 Kb
25-08-2004	New corporate identity for Peplin	35 Kb
10-08-2004	Financial Results for 2004	47 Kb
29-07-2004	Peplin on the Move	40 Kb
29-07-2004	INDs for Peplin's lead product filed with FDA	63 Kb
29-07-2004	Board changes at Peplin	59 Kb
28-07-2004	PEP005 shows highly selective activity against leukaemia	66 Kb
23-04-2004	Proposed resubmission of Investigational New Drug Applications	3 Kb
15-04-2004	Scientific peers validate PEP005 research	53 Kb
23-03-2004	Peplin Receives Notice of Allowance	3 Kb
23-03-2004	Peplin announces filing of IND	61 Kb
11-02-2004	Appointment of Michael Spooner to Board	135 Kb
11-02-2004	First Half Results	152 Kb
10-02-2004	AGN R&D Day	146 Kb